Click here for Bosulif®▼ (bosutinib monohydrate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Data in newly-diagnosed adult CML patients
Compared with imatinib, BOSULIF offers:1-3
*MMR (≤ 0.1% BCR-ABL1 transcripts on the international scale with ≥ 3000 ABL1 assessed).
†Adjusted for Sokal risk group (low, intermediate, high) and geographic region at time of random assignment. 95% CIs for ORs based on asymptotic Wald confidence limits.
‡p-value based on a Cochran–Mantel–Haenszel test for general association between treatment and response with stratification by Sokal risk group (low, intermediate, high) and region as determined at time of random assignment.
§MR4, ≤ 0.01% BCR-ABL1 transcripts on the international scale with ≥ 9800 ABL1 assessed; MR4.5, ≤ 0.0032% BCR-ABL1 transcripts on the international scale with ≥ 30,990 ABL1 assessed.
Compare 2013 guidelines to those published in 2020
Watch Prof. Richard Clark discuss the holistic approach to treatment decisions for patient with CML
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020